Table 2 Best overall response by central assessment (total study population, N = 31).

From: A Phase 2 study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer

Outcome

No. of patients with response

Rate, % (90% CI)

Objective responsea

10

32.3 (18.7–48.5)

Complete responseb

0

0 (0–9.2)

Partial responsec

10

32.3 (18.7–48.5)

Stable disease

12

38.7 (24.1–55.0)

Progressive diseased

7

22.6

Not evaluable

2

6.5

  1. aComprises patients whose best overall response was complete or partial.
  2. bDefined as disappearance of all non-nodal target lesions. Any nodal lesions must have reduction in short axis to <10 mm.
  3. cDefined as at least a 30% decrease from baseline in the sum of diameters of target lesions.
  4. dDefined as at least a 20% increase in the sum of diameters of target lesions relative to the smallest sum observed in the study and with an absolute increase of ≥5 mm in the sum.
  5. CI confidence interval.
Back to article page